

ORPHENADRINE CITRATE- orphenadrine citrate tablet
AvKARE, Inc.

Orphenadrine Citrate
Extended-release Tablets, 100 mg

Rx only

DESCRIPTION

Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2-methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. Each orphenadrine citrate tablet contains 100 mg orphenadrine citrate, USP. Orphenadrine citrate tablets also contain ethylcellulose NF, povidone USP, lactose monohydrate NF, and magnesium stearate NF.

ACTIONS

The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate also possesses anticholinergic actions.

INDICATIONS

Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo-skeletal conditions. The mode of action of the drug has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense skeletal muscles in man.

CONTRAINDICATIONS

Contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis. Contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

WARNINGS

Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine citrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.

PREGNANCY

Pregnancy category C. Safe use of orphenadrine citrate has not been established with respect to adverse effects upon fetal development. Therefore, orphenadrine citrate should be used in women of childbearing potential and particularly during early pregnancy only when in the judgement of the physician the potential benefits outweigh the possible hazards.

USAGE IN CHILDREN

Safety and effectiveness in children have not been established; therefore, this drug is not recommended for use in the pediatric age group.

PRECAUTIONS

Confusion, anxiety and tremors have been reported in a few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.

Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, or cardiac arrhythmias.

Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.

ADVERSE REACTIONS

Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.

DOSAGE AND ADMINISTRATION

TABLETS: Adults-Two tablets per day; one in the morning and one in the evening.

HOW SUPPLIED

Tablets 100 mg-Each round, white, convex tablet imprinted with "G" on one side and "2011" on the other side.

Bottles of 100 NDC 42291-530-01

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Dispense in tightly-closed, light-resistant container (USP).

Manufactured for: AvKARE, Inc.
Pulaski, TN 38478

Mfg. Rev. 01/00

AV Rev. 06/12

PRINCIPAL DISPLAY PANEL

AvKARE

NDC 42291-530-01

**Orphenadrine Citrate
Extended-Release Tablets**

100mg

100 Tablets Rx Only

USUAL DOSAGE:

See accompanying outsert for complete prescribing information.

Dispense in a tightly-closed, light-resistant container as defined in the USP, with child-resistant closure, as required.

Store at controlled room temperature, 15°C to 30°C (59°F - 86°F).

Keep this and all medication out of the reach of children.

Manufactured for:

AvKARE, Inc.
Pulaski, TN 38478

Mfg. Rev. 06/01 AV Rev. 02/13 (P)

N₃ 42291 53001 0

AVKARE
NDC 42291-530-01
**Orphenadrine Citrate
Extended-Release
Tablets**
100 mg
100 Tablets Rx Only

USUAL DOSAGE:
See accompanying outsert for complete prescribing information.
Dispense in a tightly-closed, light-resistant container as defined in the USP, with a child-resistant closure, as required.
Store at controlled room temperature, 15°- 30°C (59°- 86°F).
Keep this and all medication out of the reach of children.

Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
Mfg. Rev. 06/01 AV Rev. 02/13 (P)

N 3 42291 53001 0

ORPHENADRINE CITRATE

orphenadrine citrate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG LABEL	Item Code (Source)	NDC:42291-530(NDC:0115-2011)
Route of Administration	ORAL	DEA Schedule	

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
ORPHENADRINE CITRATE (ORPHENADRINE)	ORPHENADRINE CITRATE	100 mg

Inactive Ingredients

Ingredient Name	Strength
Ethylcelluloses	
POVIDONE	
LACTOSE MONOHYDRATE	

MAGNESIUM STEARATE**Product Characteristics**

Color	WHITE	Score	no score
Shape	ROUND	Size	9mm
Flavor		Imprint Code	G;2011
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:42291-530-01	100 in 1 BOTTLE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040368	06/24/2000	

Labeler - AvKARE, Inc. (796560394)

Revised: 2/2013

AvKARE, Inc.